16th International Conference on Dialysis. Advances in Chronic Kidney Disease 2014. January 22-25, 2014, Caesars Palace, Las Vegas, Nev.: Abstracts

2013 Blood Purification  
Hospital Infantil De Mexico Federico Gomez, Mexico DF, Mexico Purpose: To determine the frequency of CYP3A5 and MDRI gene polymorphisms and study their relationship to Tacrolimus (Tac) pharmacokinetics. Methods: Across sectional study was performed in 51 transplant children. A 12 h Tac pharmacokinetic profile (pk) was obtained with eight time sample points, DNA was obtained from peripheral blood for CYP3A5 genotyping by direct sequencing. The 51 patients were classified according to the
more » ... , as expressors CYP3A5*1*1 and CYP3A5*3*3 known as wild type and mutated allele (non-expressers). A nine pointpharmacokinetic profile of Tacrolimus was performed. Results: 22 patients (43.1%) were CYP3A5 expressers and 29 (56.8%) non expressers. The statistical analysis was performed with Kruskal-Wallis test. Twenty-two (43.1%) were CYP3A5 expressers and required high tacrolimus dose (0.12 mg/Kg/day) to appropriate tacrolimus serum levels. Twenty nine patients (56.8%) were non-expressers, they needed 0.06 mg/Kg/day. The AUC0-/dose was lower in nonexpressers patients. The trough levels, half life time and the time to reach the maximum concentration were no different between the groups.Pharmacokinetic parameters by genotype are depicted in Table 1 . Conclusion: The CYP3A5*3*3 allele frequency was 56.8% in mexican renal transplant children. The CYP3A5 gene polymorphism predicts Tac PK. 2 Introduction: Nephrotic syndrome (NS) represents 0.26% of pediatric hospitalizations in CHU Yopougon (Côte d'Ivoire-Abidjan). Pediatric NS is steroid-sensitive in 88% of cases, with relapses in 70% of cases during the taper or discontinuation of corticosteroid therapy. We describe our experience in the treatment of ergamisol for sensitive nephrotic syndrome. Methodology: This is a retrospective study from 15 children seen between February 2001 at August 2009 who had steroid-sensitive or steroid-dependent NS and received Ergamisol. Results: Nephrotic syndrome was pure in 53, 3 and 46.67% impure. The patients' mean age was 10.12 years at the time of ergamisol treatment. There were 11 males (73.3%) and all were Black race. The mean age of disease progression was 5.4 years. The Indications for using ergamisol were frequent relapses (80%), non-observance with corticosteroid therapy (7%), partial corticosensitivity (7%), and leuconeutropenia during using the cyclo-
doi:10.1159/000356547 fatcat:6rqcrwiegjavdkc3iedygopjfu